Increased glucose transporter 1 contributes to epithelial barrier dysfunction in allergic rhinitis

Area of Science:

• Immunology
• Cell Biology
• Molecular Medicine

Background:

• Epithelial barrier dysfunction is a key feature of allergic rhinitis (AR).
• The precise mechanisms underlying AR epithelial barrier impairment are not fully understood.
• This study investigates the role of glucose transporter 1 (GLUT1) in AR epithelial barrier function.

Purpose of the Study:

• To assess the impact of glucose transporter 1 (GLUT1) on epithelial barrier function in allergic rhinitis (AR).
• To explore the relationship between GLUT1 expression and AR severity.
• To evaluate the therapeutic potential of GLUT1 inhibition in AR.

Main Methods:

• Proteomics analysis of nasal mucosa from AR patients and healthy controls.
• Immunofluorescence, western blotting, and RT-qPCR for protein and gene expression validation.
• In vitro studies using nasal epithelial cells and an in vivo AR mouse model to assess GLUT1 inhibition.

Main Results:

• Proteomics identified GLUT1 as significantly upregulated in AR patients' nasal mucosa.
• Elevated GLUT1 expression in AR epithelial cells correlated with disease severity and reduced barrier proteins (ZO-1, occludin).
• In vitro and in vivo studies demonstrated that GLUT1 inhibition restored barrier protein expression, reduced inflammation, and improved barrier function.

Conclusions:

• Allergic rhinitis exhibits a unique protein expression profile with increased GLUT1 linked to barrier dysfunction.
• GLUT1 inhibition emerges as a promising therapeutic strategy for allergic rhinitis by restoring epithelial barrier integrity and reducing inflammation.